TAKTIC:LY2780301(p70S6K/AKT抑制剂)联合每周紫杉醇治疗HER2阴性晚期乳腺癌的前瞻性多中心非对照IB/II期研究
TAKTIC是一项多中心、非对照IB/II期研究,入组51例HER2阴性晚期乳腺癌患者,口服LY2780301每日一次联合每周静脉紫杉醇。IB期确定II期推荐剂量为LY2780301 500 mg每日一次联合紫杉醇80 mg/m2;II期6个月客观缓解率在总体人群为63.9%[48.8-76.8],在PI3K/AKT通路激活亚组为55%[35-73.7]。结论认为该联合方案可行,并在总体人群和PI3KAKT+亚组中均有初步疗效证据。
要点
- IB期确定的II期推荐剂量为LY2780301 500 mg每日一次联合紫杉醇80 mg/m2。
- IB期主要药物相关不良事件包括神经病变(75%,3-4级8%)、乏力(58%,无3-4级)和甲毒性(50%,3-4级25%)。
- II期6个月客观缓解率总体人群63.9%[48.8-76.8],PI3KAKT+亚组55%[35-73.7]。
核心结论
- 在HER2阴性晚期乳腺癌患者中,LY2780301联合每周紫杉醇可行,并在总体人群和PI3KAKT+亚组中均有初步疗效证据。
研究设计与样本
- 多中心、非对照IB/II期试验,入组HER2阴性晚期乳腺癌患者,IB期允许既往接受过晚期疾病细胞毒治疗,II期不允许。
- 口服LY2780301每日一次联合静脉每周紫杉醇给药;IB期主要终点为确定II期推荐剂量,II期主要终点为估计6个月客观缓解率(总体人群及PI3K/AKT通路激活者)。
- 共入组51例患者。
主要发现
- II期推荐剂量为LY2780301 500 mg每日一次联合紫杉醇80 mg/m2。
- IB期主要药物相关不良事件:神经病变75%(3-4级8%)、乏力58%(无3-4级)、甲毒性50%(3-4级25%)。
- II期不良事件与IB期相似,但14%患者发生肺炎(3-4级6%)。
- II期6个月客观缓解率:总体人群63.9%[48.8-76.8],PI3KAKT+亚组55%[35-73.7]。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAKTIC study aimed at exploring the combination of paclitaxel and LY2780301 in this population. METHODS: In this multicentric phase Ib/II trial, we enrolled patients with HER2-negative ABC, with (phase IB) or without (phase II) prior to cytotoxic treatment for advanced disease. Oral LY2780301 was administered once daily in combination with intravenous weekly paclitaxel. Primary endpoints were to determine the recommended phase II dose (RP2D) of the combination of LY2780301 with weekly paclitaxel (phase Ib), and to estimate a 6 months objective response rate (ORR) (phase II) in patients with HER2-negative ABC, both in the overall patient population and in cases with activation of the PI3K/AKT pathway (PI3KAKT+). RESULTS: A total of 51 patients were enrolled; RP2D was LY2780301 500 mg QD+ paclitaxel 80 mg/m2. Main drug-related adverse events noted in phase Ib included neuropathy (75% of patients, grade 3-4 in 8%), asthenia (58% of patients, no grade 3-4), and ungual toxicity (50% of patients, grade 3-4 in 25%). They were similar in the phase II part, except that 14% of patients experienced pneumonia (grade 3-4 in 6%). In the phase II part, 6-month ORR in the overall population and in PI3KAKT+ subgroup were, respectively, 63.9% [48.8-76.8] and 55% [35-73.7]. CONCLUSION: Combining LY2780301 and weekly paclitaxel in patients with HER2-negative ABC was feasible with preliminary evidence of efficacy in both the overall population and the PI3KAKT+ subgroup. TRIAL REGISTRATION ID: NCT01980277.
引用
- Vicier C, Sfumato P, Isambert N, et al. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. Eur J Cancer. 2021. PMID: 34781168. doi:10.1016/j.ejca.2021.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。